Home/Hsiri Therapeutics/William Claypool, M.D.
WC

William Claypool, M.D.

Chairman and CEO

Hsiri Therapeutics

Hsiri Therapeutics Pipeline

DrugIndicationPhase
Mycobacterial Diseases ProgramTuberculosis (TB) and Non-Tuberculous Mycobacterial (NTM) InfectionsPre-clinical
Drug-Resistant Bacterial Infections ProgramInfections due to usual bacterial pathogens resistant to current treatmentsResearch/Pre-clinical
Drug-Resistant Fungal Infections ProgramInfections due to drug-resistant fungal pathogensResearch/Pre-clinical